top of page

From ACEI to ARB: What to Do When Angioedema Strikes

🛑 What to Do When ACE Inhibitors Cause Angioedema


1. Immediate Action:

  • Discontinue the ACE inhibitor immediately (e.g., enalapril, lisinopril, ramipril).

  • Provide supportive care:

    • Protect the airway (priority).

    • Administer oxygen, antihistamines, corticosteroids, and epinephrine if airway compromise is suspected — although effectiveness may be limited due to the non-histaminergic, bradykinin-mediated nature of the reaction.

    • Admit to hospital if symptoms are progressing or if airway involvement is suspected.


🧬 Why It Happens

  • ACE inhibitors block the degradation of bradykinin, a vasodilator that increases vascular permeability, leading to angioedema.

  • This reaction is not allergic, and typically lacks urticaria or itching.


✅ What Medication Can Be Used Next?

Angiotensin Receptor Blockers (ARBs) such as losartan, valsartan, or candesartan are often considered next-line therapy.


✅ What Medication Can Be Used Next?


Angiotensin Receptor Blockers (ARBs), such as losartan or valsartan, can be considered as alternatives, but with caution.

🔍 Why?

  • ARBs do not inhibit bradykinin breakdown, so the risk is much lower.

  • However, studies (including the Annals of Allergy article) show that 0.1–10% of patients who had angioedema with ACE inhibitors may also experience angioedema with ARBs.

📌 Guidance:

  • Wait at least 4 weeks after resolution of ACEI-induced angioedema before starting an ARB.

  • Start under supervision, and counsel the patient about the small but real risk of recurrence.


🚫 Should ARBs Be Avoided?

Not necessarily.

  • Clinical guidelines suggest ARBs can be cautiously used, particularly when no alternative exists and the ACEI was essential (e.g., for heart failure or proteinuric kidney disease).

  • Avoid ARBs in patients with a history of severe or life-threatening angioedema unless the benefit clearly outweighs the risk.



📌 Clinical Recommendations

Step

Action

ACEI causes angioedema

Discontinue the ACE inhibitor immediately

Management

Airway protection + supportive care

Mechanism

Bradykinin-mediated (not histamine-mediated)

Risk with ARBs

Significantly lower; recurrence is rare

Consider ARB use

Yes, cautiously — after full resolution and with informed consent

Timing for ARB initiation

Wait at least 4 weeks after angioedema resolves

Avoid ARBs if

Previous angioedema was severe/life-threatening unless strongly indicated


🧠 Key Takeaway

While ACE inhibitors can cause bradykinin-mediated angioedema, most patients can safely switch to an ARB under supervision, especially if the original indication for RAAS blockade (e.g., heart failure, CKD) remains important. The risk of recurrence is low, and not switching to ARBs unnecessarily may deprive patients of vital long-term benefits.


📚 References

Comments

bottom of page